Samantha Colledge1, Amy Peacock2, Janni Leung3, Sarah Larney2, Jason Grebely4, Matthew Hickman5, Evan Cunningham4, Adam Trickey5, Jack Stone6, Peter Vickerman6, Louisa Degenhardt2. 1. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. Electronic address: s.colledge@student.unsw.edu.au. 2. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. 3. National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia; School of Psychology, The University of Queensland, Brisbane, Australia. 4. Kirby Institute, University of New South Wales, Sydney, Australia. 5. Population Health Sciences, University of Bristol, Bristol, United Kingdom; National Institute of Health Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation of Interventions, United Kingdom. 6. Population Health Sciences, University of Bristol, Bristol, United Kingdom.
Abstract
BACKGROUND: People who inject drugs (PWID) are at an elevated risk of fatal overdose in the first year after experiencing a non-fatal event. Such non-fatal events may also result in overdose-related sequelae, ranging from physical injury to paralysis. Given variation in drug markets and treatment availability across countries and regions, we may see similar variations in non-fatal overdose prevalence. Monitoring non-fatal overdose prevalence among PWID is essential for informing treatment intervention efforts, and thus our review aims to estimate the global, regional, and national prevalence of non-fatal overdose, and determine characteristics associated with experiencing such an event. METHODS: We conducted a systematic review and meta-analyses to estimate country, regional, and global estimates of recent and lifetime non-fatal overdose prevalence among PWID. Using meta-regression analyses we also determined associations between sample characteristics and non-fatal overdose prevalence. RESULTS: An estimated 3.2 (1.8-5.2) million PWID have experienced at least one overdose in the previous year. Among PWID, 20.5% (15.0-26.1%) and 41.5% (34.6-48.4%) had experienced a non-fatal event in the previous 12 months and lifetime respectively. Frequent injecting was strongly associated with PWID reporting recent and lifetime non-fatal overdose. Estimates of recent non-fatal overdose were particularly high in Asia and North America. CONCLUSION: Around one in five PWID are at an elevated risk of fatally overdosing every year, however there is substantial geographical variation. In countries with higher rates of non-fatal overdose there is need to introduce or mainstream overdose prevention strategies such as opioid agonist treatment and naloxone administration training programs.
BACKGROUND:People who inject drugs (PWID) are at an elevated risk of fatal overdose in the first year after experiencing a non-fatal event. Such non-fatal events may also result in overdose-related sequelae, ranging from physical injury to paralysis. Given variation in drug markets and treatment availability across countries and regions, we may see similar variations in non-fatal overdose prevalence. Monitoring non-fatal overdose prevalence among PWID is essential for informing treatment intervention efforts, and thus our review aims to estimate the global, regional, and national prevalence of non-fatal overdose, and determine characteristics associated with experiencing such an event. METHODS: We conducted a systematic review and meta-analyses to estimate country, regional, and global estimates of recent and lifetime non-fatal overdose prevalence among PWID. Using meta-regression analyses we also determined associations between sample characteristics and non-fatal overdose prevalence. RESULTS: An estimated 3.2 (1.8-5.2) million PWID have experienced at least one overdose in the previous year. Among PWID, 20.5% (15.0-26.1%) and 41.5% (34.6-48.4%) had experienced a non-fatal event in the previous 12 months and lifetime respectively. Frequent injecting was strongly associated with PWID reporting recent and lifetime non-fatal overdose. Estimates of recent non-fatal overdose were particularly high in Asia and North America. CONCLUSION: Around one in five PWID are at an elevated risk of fatally overdosing every year, however there is substantial geographical variation. In countries with higher rates of non-fatal overdose there is need to introduce or mainstream overdose prevention strategies such as opioid agonist treatment and naloxone administration training programs.
Authors: Carlos Blanco; Mir M Ali; Aaron Beswick; Karen Drexler; Cheri Hoffman; Christopher M Jones; Tisha R A Wiley; Allan Coukell Journal: NAM Perspect Date: 2020-10-26
Authors: Jeanette M Bowles; Sonia Jain; Xiaoying Sun; Steffanie A Strathdee; Kora DeBeck; M-J Milloy; Zachary Bouck; Dan Werb Journal: Int J Drug Policy Date: 2021-08-12
Authors: Felipe Castillo; Daniel Scalise; David Hernandez; Rahul Gupta; Cale N Basaraba; Thomas Corbeil; Sandra D Comer; Andres R Schneeberger Journal: J Addict Dis Date: 2022-04-22
Authors: Kristin E Schneider; Catherine Tomko; Danielle Friedman Nestadt; Bradley E Silberzahn; Rebecca Hamilton White; Susan G Sherman Journal: Int J Drug Policy Date: 2020-07-22
Authors: Lauren Dayton; Alyona Mazhnaya; Kristin E Schneider; Xiangrong Kong; Abigail Winiker; Melissa Davey-Rothwell; Karin E Tobin; Carl A Latkin Journal: Drug Alcohol Depend Date: 2021-02-22 Impact factor: 4.492
Authors: Sean T Allen; Kristin E Schneider; Alyona Mazhnaya; Rebecca Hamilton White; Allison O'Rourke; Alex H Kral; Ricky N Bluthenthal; Michael E Kilkenny; Susan G Sherman Journal: AIDS Behav Date: 2021-06-02
Authors: Ayden I Scheim; Ruby Sniderman; Ri Wang; Zachary Bouck; Elizabeth McLean; Kate Mason; Geoff Bardwell; Sanjana Mitra; Zoë R Greenwald; Kednapa Thavorn; Gary Garber; Stefan D Baral; Sean B Rourke; Dan Werb Journal: J Urban Health Date: 2021-06-28 Impact factor: 3.671
Authors: Katie Kanter; Ryan Gallagher; Feyisope Eweje; Alexander Lee; David Gordon; Stephen Landy; Julia Gasior; Haideliza Soto-Calderon; Peter F Cronholm; Ben Cocchiaro; James Weimer; Alexis Roth; Stephen Lankenau; Jacob Brenner Journal: Harm Reduct J Date: 2021-07-23
Authors: Rachel E Gicquelais; Dan Werb; Charles Marks; Carolyn Ziegler; Shruti H Mehta; Becky L Genberg; Ayden I Scheim Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 4.280
Authors: Janna Ataiants; Silvana Mazzella; Alexis M Roth; Lucy F Robinson; Randall L Sell; Stephen E Lankenau Journal: J Interpers Violence Date: 2020-06-14